(Q33895825)

29 July 2017

Developing safety criteria for introducing new agents into neoadjuvant trials (English)

1 reference

29 July 2017

18

Olufunmilayo Olopade

1 reference

29 July 2017

25

Laura Esserman

1 reference

29 July 2017

20

Barbara A Parker

1 reference

29 July 2017

23

Hope Rugo

1 reference

29 July 2017

16

Minetta C Liu

1 reference

29 July 2017

Angela DeMichele

1

1 reference

29 July 2017

Donald A Berry

2

1 reference

29 July 2017

JoAnne Zujewski

3

1 reference

29 July 2017

Sally Hunsberger

4

1 reference

29 July 2017

Larry Rubinstein

5

1 reference

29 July 2017

Joseph E Tomaszewski

6

1 reference

29 July 2017

Gary Kelloff

7

1 reference

29 July 2017

Jane Perlmutter

8

1 reference

29 July 2017

Meredith Buxton

9

1 reference

29 July 2017

Julia Lyandres

10

1 reference

29 July 2017

Kathy S Albain

11

1 reference

29 July 2017

Chris Benz

12

1 reference

29 July 2017

A Jo Chien

13

1 reference

29 July 2017

Paul Haluska

14

1 reference

29 July 2017

Brian Leyland-Jones

15

1 reference

29 July 2017

Pamela Munster

17

1 reference

29 July 2017

John W Park

19

1 reference

29 July 2017

Lajos Pusztai

21

1 reference

29 July 2017

Debu Tripathy

22

1 reference

29 July 2017

Douglas Yee

24

1 reference

29 July 2017

language of work or name

English

0 references

publication date

7 March 2013

1 reference

29 July 2017

Clinical Cancer Research

1 reference

29 July 2017

19

1 reference

29 July 2017

11

1 reference

29 July 2017

2817-2823

1 reference

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Drug development and clinical trials--the path to an approved cancer drug

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Adaptive clinical trials in oncology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Economics of new oncology drug development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096560

Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens

29 October 2018

1 reference

12 December 2020

ANTAGONISM OF MONOAMINE OXIDASE INHIBITORS AGAINST NOREPINEPHRINE ACETYLCHOLINE AND POTASSIUM IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT

1 reference

12 December 2020

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

12 December 2020

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

12 December 2020

Adaptive clinical trials: the promise and the caution

1 reference

12 December 2020

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

1 reference

12 December 2020

Accelerating identification and regulatory approval of investigational cancer drugs

1 reference

12 December 2020

The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research

1 reference

12 December 2020

Pathological complete response and accelerated drug approval in early breast cancer

1 reference

12 December 2020

10.1158/1078-0432.CCR-12-2620

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference